The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that. Ruxolitinib cream, a JAK1/JAK2 inhibitor developed by Incyte is currently undergoing the FDA’s priority review. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.Compared to oral JAK inhibitors, RPT193 has an attractive risk-benefit profile as an oral therapy, the analysts wrote.Reiterating the overweight rating, the analyst Alethia Young and the team note that the company has exceeded its internal targets for the experimental therapy in terms of Eczema Area and Severity Index (EASI) score and pruritis improvement.
The new target at $71.00 up from $51.00 per share previously implies a premium of ~282.3% to the last close.In reaction, Cantor Fitzgerald has raised the price target for the stock by more than a third as the analysts increase the probability of success for the treatment to 50% from 25%,.
0 kommentar(er)
